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COMPOSITIONS AND METHODS FOR
DETECTING AND TREATING
ATHEROSCLEROSIS

IIA (classically referred to as non-pancreatic secretory PLA2)
has been proposed as a mediator of in?ammatory responses.
During acute or chronic in?ammation, the concentration of
Group IIA sPLA2 can increase by over 100-fold in in?amma

This application claims the bene?t of priority to Provi

FIELD OF THE INVENTION

tory ?uids and plasma. The expression of group IIA sPLA2 is
Widely distributed in human tissues. In the arterial Wall, group
IIA sPLA2 is expressed by vascular smooth muscle cells and
is associated With heparin sulfate proteoglycans of the ECM
Recently, a distinct sPLA2 in macrophages and mast cells

The invention relates to compositions and methods for the
detection and treatment of atherosclerosis. In particular, the
invention relates to compositions containing an inhibitor or

has been described. Although it Was previously assumed that
the sPLA2 in macrophages and mast cells is Group IIA, it is
noW recogniZed that Group V sPLA2 is expressed by these
cells. Like the Group IIA enZyme, Group V sPLA2 mRNA is

antibody that binds speci?cally to Group V secretory phos

greatly induced by proin?ammatory stimuli. Group V sPLA2

sional Application 60/382,563, ?led May 24, 2002, Which is
incorporated by reference in its entirety.

pholipase (sPLA2).

exhibits high af?nity binding to proteoglycans that is medi
ated by a cluster of cationic residues near the C-terminal end
of the enZyme. The studies of Balboa et al. demonstrate that

BACKGROUND OF THE INVENTION

A critical event in early atherogenesis is the retention of

loW density lipoprotein (LDL) particles in the subendothe
lium through their binding intimal proteoglycans. These

20

an antisera raised against the synovial sPLA2 (Group IIA)
cross-reacts With Group V sPLA2 in P388Dl macrophages.
This observation underscores the importance of developing
molecular probes and antibodies to distinguish the individual

retained lipoprotein particles are exposed to several modify

enzymes.

ing enZymes in the arterial Wall, including lipases, oxidiZing

Immunohistochemistry studies have established that
sPLA2 is present in normal arterial tissue and increased in

enZymes, and proteases. A multitude of biological responses
to such modi?ed LDL, including the recruitment and lipid
loading of macrophages, leads to the initiation and progres
sion of atherosclerosis. The extracellular matrix (ECM)
appears to play an active role in this process by not only
mediating the retention of LDL particles, but by also modu
lating the activity of various enZymes toWards LDL. Thus, in

25

30

regions Where LDL is being accumulated, the co-localiZation

ros1s.

lipolytic enZymes and oxidiZing agents that are capable of
modifying LDL. The activity of these factors is likely respon
sible for the prominent characteristics of LDL particles iso
lated from atherosclerotic lesions, namely oxidation, enrich
ment With sphingomyelin, and self-aggregation.
Accumulating evidence points to LDL aggregation and

35

structural features that may exert important functional differ
ences. Group V sPLA2 contains amino acid variations in the
regions that have been shoWn to be important for the interfa

cial binding of other sPLAZs. Binding studies using phos
phatidylcholine (PC)-coated hydrophobic beads shoWed that
human Group V sPLA2 binds PC membranes more than
40

50-times more tightly than human Group IIA sPLA2. Indeed,
it has been suggested that PC analogues may serve as selec

fusion as elements of atherogenic lipid accumulation in the
artery Wall. Aggregated lipoproteins that appear to be derived
from LDL are prominent in early atherosclerotic lesions.
Aggregated LDL is taken up by macrophages in vitro at an
enhanced rate compared to non-aggregated LDL, leading to
macrophage cholesterol accumulation and foam cell forma
tion. Since native LDL particles do not form aggregates, LDL

45

modi?cation appears to be a prerequisite for aggregation and
fusion. It is notable that the aggregation/fusion of LDL par
ticles proceeds faster in vitro When they are bound to pro

50

tive inhibitors for Group V sPLA2, given the loW binding
a?inity of other sPLA2s for PC substrates. In contrast to
Group IIA sPLA2, Which has been shoWn to be very ineffec

tive in hydrolyZing PC compared to other phospholipids,
kinetic studies shoW that Group V sPLA2 effectively hydro

lyZes PC-containing substrates.
Thus, there is a need for probes and methods to distinguish
the Group IIA and Group V sPLA2. There is also a need for
methods and compositions to block LDL modi?cations that
lead to LDL aggregation and/or fusion and increased mac

teoglycans, and in turn, proteoglycan binding of modi?ed

rophage LDL uptake.

LDL is enhanced as a result of particle aggregation. Studies in
vitro have demonstrated that treatment of LDL With sPLA2

and secretory sphingomyelinase (s-SMase), induces LDL

dominantly associated With smooth muscle cells, Whereas in
other reports, a signi?cant amount is detected in macroph
ages. A possible explanation for the contradictory results may
be the variable degree to Which available antibodies recogniZe

Group IIA sPLA2 and the related form, Group V sPLA2.
Group V sPLA2 shoWs a close structural relationship to
Group IIA sPLA2. Nevertheless, these enZymes have distinct

of LDL, ECM and LDL modifying enzymes leads to a self
perpetuating cascade of events that culminates in atheroscle
Within the arterial intima there are several proteolytic and

atherosclerotic lesions. HoWever, there are some inconsisten

cies betWeen these reports. In some reports, sPLA2 is pre

SUMMARY OF THE INVENTION
55

aggregation and/ or fusion and enhanced retention in the sub

In one aspect of the invention there is provided an antibody

endothelium (Oomi, K et al., J Lipid Res, 2000. 41 (1 1):1703

raised against mouse Group V sPLA2 that speci?cally binds
to lesional macrophages.

14).
The phospholipases A2 (PLA2) family comprises a group
of enZymes sharing the common feature of hydrolyZing the

60

In another aspect of the invention there is provided a
method of assessing the risk of cardiovascular pathology in a

65

patient comprising administering to the patient a monoclonal
antibody speci?c for the human Group V sPLA2 enZyme, said
antibody having a detectable label attached thereto; quanti
fying the amount of Group V sPLA2 in plasma of a human
patient and correlating the amount of Group V sPLA2 With the

fatty acid esteri?ed at the sn-2 position of glycerophospho
lipids. (Six, DA. and B. A. Dennis, Biochem. Biophys.Act.,
2000. 1488: 1-19). They are generally categoriZed into cyto
solic or secretory forms. The secreted forms of the enZyme are

of loW molecular Weight (14 kDA), highly enriched in disul
?de bonds, and require 1-10 mM calcium for activity. The
major secreted form present in synovial ?uid, termed Group

presence of unstable atherosclerotic plaques in the cardiovas

cular system of the patient.

US 7,521,198 B1
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In yet another aspect of the invention there is provided a
method for blocking the formation of aggregates of LDL in a
patient, said method comprising administering to a patient an
effective amount of an inhibitor of Group V sPLA2.
In another aspect of the invention there is provided a

sclerotic lesions, is one of the most potent inducers of mac

rophage foam cell formation in vitro. These modi?ed LDL
particles are engulfed by macrophages in a process that
involves the actin cytoskeleton. Thus, although it has not been
directly shoWn, sPLA2 activity on LDL may promote athero

method for preventing atherosclerotic lesion development,

genesis by generating potent inducers of macrophage foam

said method comprising administering to a patient an effec
tive amount of an inhibitor of Group V sPLA2.

cells in the arterial subendothelium. Which sPLA2 enZyme(s)
produce these effects on LDL in vivo has not been conclu

sively established.
BRIEF DESCRIPTION OF THE DRAWINGS

Group IIA sPLA2 has been shoWn to be present in athero
sclerotic lesions associated With the ECM. Smooth muscle
cells appear to be the main source of Group IIA sPLA2 in the

FIG. 1A and FIG. 1B are schematic draWings of a proposed

model for the role of Group V sPLA2 in promoting macroph

arterial Wall. Although human recombinant Group IIA sPLA2
is capable of hydrolyZing LDL in vitro, the activity of this

age foam cell formation.

FIGS. 2A (human) and 2B (mouse) shoW atherosclerotic
lesions stained for either a macrophage-speci?c antigen

enZyme toWards LDL is loW When compared to the hydrolysis
mediated by bee venom sPLA2. It is notable that C57BL/6
mice, a strain susceptible to diet-induced atherosclerosis, lack
functional Group IIA sPLA2 as a result of a natural disruption
of the gene.

(CD68, FA11) or Group V sPLA2. 40>< magni?cation.
FIG. 3 is a bar graph shoWing sPLA2 activity produced by
control and AdmGV-treated RAW and J 774 cells.

FIG. 4A is a bar graph shoWing the free fatty acid (FFA)

20

content of media after 24 hours incubation of COS-7 cells

We noW shoW the presence of an additional sPLA2 in ath

Group V sPLA2.

erosclerotic lesions, Group V sPLA2, Which is shoWn herein
to be associated speci?cally With macrophages. These results
suggest that the presence of Group V sPLA2 and LDL in the
proximity of macrophages leads to the localiZed production
of modi?ed LDL particles that have enhanced capacity for
macrophage uptake, Which consequently leads to foam cell

FIGS. 6A and 6B are bar graphs shoWing the siZe distribu
tion of unmodi?ed and Group V-modi?ed LDLs as assessed

formation and enhanced atherosclerosis.
The data provided herein suggest that LDL retained in the

(AdmGV-treated and untreated) With 0.2 mg/ml LDL. FIG.
4B is an autoradiograph shoWing siZe distribution of LDL

particles after incubation.
FIG. 5 is a graph shoWing LDL hydrolysis by puri?ed

25

by electron microscopy.
FIG. 7 shoWs the separation of LDLs before and after

subendothelium is susceptible to hydrolysis by macrophage
30

treatment With Group V sPLA2 by siZe exclusion chromatog

raphy.
FIG. 8 is a graph shoWing that the degree of particle aggre
gation corresponds to the extent of particle hydrolysis.
FIG. 9 is a series of photographs of peritoneal macrophages

are susceptible to self-aggregation and fusion. In the arterial

Wall, sphingomyelinase and/or ECM promotes Group V
35

from C57BL/ 6 mice that Were incubated With non-modi?ed

(mock) LDL, vortexed LDL, or Group V sPLA2-modi?ed
With Oil Red 0 and analyZed by light microscopy at 40x

Group V sPLA2 provides an important neW target for the
40

FIG. 10 is a Coomassie blue stained SDS 15% polyacry

lamide gel on Which mouse Group V sPLA2 expressed in
prokaryotic cells Was separated. The predicted molecular

Weight of the Group V sPLA2 fusion protein expressed in the
bacterial cells is ~17 kDa.
FIG. 11 is an immunoblot of control COS-7 cells and cells

45

after infection With AdmGV, Which expresses Group V
sPLA2. Cells Were infected With an MOI of 40 pfu per cell.

Aliquots corresponding to 10 micrograms of protein Were
separated on 15% SDS PAGE, immunoblotted With rabbit

sPLA2-mediated effects on LDL aggregation and fusion. It is
believed that modi?ed LDL particles are taken up by mac
rophages to a greater extent than native LDL and that the

mechanism of uptake of aggregated/fused particles is distinct
from receptor-mediated endocytosis of native LDL. Thus,

LDL (~30% hydrolyZed) for 48 hours. Cells Were stained

magni?cation.

secreted Group V sPLA2 leading to the formation of small,
dense LDL particles. These sPLA2-modi?ed LDL particles

50

anti-mouse Group V sPLA2, and visulaiZed by chemilumi
nescence.

treatment of atherosclerotic disease. Use of inhibitors of

Group V sPLA2 to prevent the formation of aggregates of
LDL is encompassed by the present invention. Such inhibi
tors include, but are not limited to anti-Group V sPLA2 anti
bodies, other compounds, such as phosphatidylcholine ana
logs, that bind to Group V sPLA2 and antisense
oligonucleotides that speci?cally bind to and prevent trans
lation of Group V sPLA2 mRNA. Such compounds can be

identi?ed by testing compounds for their ability to bind to
Group V sPLA2 and inhibit LDL modi?cation in vitro.
The speci?c dose of an inhibitor compound administered
according to this invention to obtain therapeutic or prophy
lactic effects Will, of course, be determined by the particular

circumstances surrounding the case, including, for example,
DETAILED DESCRIPTION OF THE INVENTION
55

Several lines of evidence suggest that sPLA2 modi?cation
of LDL results in structural alterations of the particle that lead
to atherogenic lipid accumulation in the subendothelium.
Studies in vitro indicate that lipolysis of LDL With sPLA2

results in partial liproprotein aggregation and increased a?in
ity for proteoglycans. These effects are likely brought about
by conformational changes in the apoB-100 moiety of LDL.
In addition, sPLA2 modi?cation increases the susceptibility
of LDL to hydrolysis by secretory sphingomyelinase

60

(s-SMase). This leads to the accumulation of ceramide Within

65

the particles, Which can also promote particle aggregation and
fusion. Aggregated/ fused LDL, Which is prominent in athero

the compound administered, the route of administration and
the condition being treated. Typical daily doses Will contain a
non-toxic dosage level of from about 0.01 mg/kg to about 50
mg/kg of body Weight of an active compound of this inven
tion.
Preferably inhibitor compounds or pharmaceutical formu
lations containing these compounds are in unit dosage form
for administration to a mammal. The unit dosage form can be
a capsule or tablet itself, or the appropriate number of any of
these. The quantity of active ingredient in a unit dose of
composition may be varied or adjusted from about 0.1 to
about 1000 milligrams or more according to the particular
treatment involved. It may be appreciated that it may be

necessary to make routine variations to the dosage depending

US 7,521,198 B1
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on the age and condition of the patient. The dosage Will also

With AdmGV or control virus, Adnull. TWenty-four hours

depend on the route of administration.
The compound can be administered by a variety of routes

after adenovirus treatments, cells Were incubated an addi

tional 24 hours With media containing 0.2 mg/ml 125l-LDL
(0.4 pM). The extent of LDL hydrolysis Was assessed by
measuring the free fatty acid (FFA) content of media. As

including oral, aerosol, rectal, transdermal, subcutaneous,
intravenous, intramuscular, and intranasal.
Group V sPLA2 is shoWn herein to associate speci?cally
lesions. The proposed role of Group V sPLA2 in promoting
the accumulation of atherogenic lipid in the developing ath

shoWn in FIG. 4A, a signi?cant amount of FFA Was liberated
When LDL Was added to Group V sPLA2-expressing cells.
The data indicate that approximately 85 molecules of FFA
Were generated per particle of LDL added. Analysis by non

erosclerotic plaque is shoWn in FIG. 1. In the proposed model
native LDL in the circulation migrates into the intima and

incubated With Group V sPLA2-expressing cells migrated as

With macrophages in human and mouse atherosclerotic

denaturing gradient gel electrophoresis shoWed that LDLs

associates With proteoglycans. Group V sPLA2 secreted by

smaller lipoprotein particles compared to control LDLs (FIG.

macrophages also bind proteoglycans, Where it has the capac
ity to hydrolyZe phospholipids on LDL. Group V sPLA2
modi?ed LDL binds proteoglycans With higher a?inity and is

4B).
Group V sPLA2-Modi?ed LDL Undergoes Spontaneous
Aggregation and Promotes Macrophage Foam Cell Forma

subject to further modi?cations, leading to aggregation/fu
sion of particles. Such LDL modi?cations promote uptake by
macrophages, leading to foam cells.
A monoclonal antibody speci?c for the human Group V
enZyme is shoWn herein to clearly stain macrophages in
human atherosclerotic lesions. A polyclonal antibody raised
against mouse Group V sPLA2 also demonstrates speci?c

tion

Partially puri?ed Group V sPLA2 enZyme Was prepared
from media collected from AdmGV-treated COS cells by
20

material Was assessed using POPG and LDL as substrates.

staining of lesional macrophages in a mouse that lacks Group

11A sPLA2. FIG. 2 shoWs immunostaining of Group V sPLA2
in human (A) and mouse (B) atherosclerotic lesions. FA-l 1 is
a monoclonal antibody Which is speci?c for macrosialin, the
mouse homologue of the human macrophage-speci?c anti
gen CD68. Serial sections treated With no primary antibody
(A) or pre-immune antisera (B) shoWed no staining. Such

25

antibodies canbe used to detect atherosclerotic plaques and to

30

35

40

45

Group V sPLA2, AdmGV, Was constructed using methods

Cloning, A Laboratory Manual for methods; Genbank for
50

With Group V sPLA2 (~70% phospholipids hydrolyZed) Were

Were treated With AdmGV at a multiplicity of infection

lipase activity using a coliormetric assay (WAKO). Mixed

separated on a Superose 6 column, and the cholesterol content
of 0.5 ml fractions Was determined. (inset of FIG. 7): Nega
55

erol (POPG), deoxycholate and noniodet-40 Were used as

degree of particle aggregation is proportional to the percent of
phospholipids hydrolyZed. An analysis of Group V sPLA2

substrate. Values Were expressed as the amount of FFA
60

hydrolyZed LDL particles shoWs a positive correlation
betWeen the extent of particle hydrolysis and the degree of

particle aggregation. FIG. 8.
Aggregated LDL, such as that produced by vortexing, has

respectively.
LDL is HydrolyZed by Mouse Group V sPLA2 Expressed by
Adenoviral Vector

tive staining and electron microscopy of mGV sPLAZ-modi
?ed LDL particles is shoWn in FIG. 7.
Further analysis of sPLA2-modi?ed LDL revealed that the

micells comprising 1-palmitoyl, 2-oleoyl phosphatidylglyc
released in the assay per ml of culture media. At the higher
dose of adenovirus, sPLA2 activity Was increased over base
line values 4.4-fold and 42-fold in RAW and 1774 cells,

by electron microscopy. FIG. 7.
Aliquots containing 75 pg unmodi?ed LDL or LDL treated

pholipase activity in mouse macrophage lines (FIG. 3). Cells
(MOI) of 40 or 100 pfu per cell. After 48 hours of treatment,
culture supernatants Were collected and assayed for phospho

Group V sPLA2 are signi?cantly smaller compared to control
LDLs. This ?nding is signi?cant, since small dense LDL
particles have increased a?inity for proteoglycans and are
thereby retained in the vessel Wall subendothelium. Mean
diameters (:SD) of unmodi?ed and modi?ed LDLs (~200
particles per group) Were 27.7 (10.25) nm and 25.3 (10.29)
nm, respectively (P<0.001). FIGS. 6A and 6B.
To assess Whether hydrolysis leads to spontaneous particle
aggregation and/or fusion, LDLs Were separated before and
after treatment With Group V sPLA2 by siZe exclusion chro
matography. Aggregated/ fused particles elute in the void vol
ume of a Superose 6 gel ?ltration column. The analysis of
unmodi?ed LDL and maximally modi?ed LDL shoWed that a
large portion (>50%) of the modi?ed LDL Was in an aggre
gated form. The presence of LDL aggregates Was con?rmed

knoWn to those of skill in the art (see Maniatis, Molecular
mouse Group V sPLA2 nucleotide sequence) and used to
investigate the effect of AdmGV treatment on secreted phos

LDL, this represents ~70% hydrolysis by Group V sPLA2.
Analysis of LDL particles by electron microsopy after
negative staining shoWed that LDL particles hydrolyZed by

antibody that binds to the anti-Group V sPLA2 antibody can
be used to detect the bound anti-group V sPLA2 antibody.

replication-de?cient adenoviral vector encoding mouse

FFA per pg LDL. Assuming 1.4 nmol phospholipid per pg
FIG. 5.

antibody can be tagged With a detectable label or a second

Use of viral vectors provides a rapid and ef?cient technique
for over-expressing proteins in macrophages, a cell type that
is di?icult to stably transfect using plasmid constructs. A

added enZyme. The amount of FFA acids generated Was mea

At maximal hydrolysis, GroupV sPLA2 generated ~1 nmol

VsPLA2 in the plasma. The anti-Group V sPLA2 speci?c

Development ofAdenoviral Vector Expressing Mouse Group
V sPLA2

LDL (0.5 mg/ml; 1 pM) Was incubated for 20 hours at 37° C.
in buffer containing 6 mM HEPES, 6 mM CaCl2, 2.4 mM
MgCl2, 84 mM NaCl and 2% (Wt/vol) BSA With and Without
sured using a colorimetric assay. One unit of GV sPLA2 Will
generate 1 nmole of FFA per minute using POPG as substrate.

quantitate the amount of Group V sPLA2 in plasma. For
example, an anti-Group V sPLA2 antibody may be added to a
tissue or plasma sample obtained from a patient in order to
detect the presence of Group V sPLA2. The amount of anti
body detected can then be correlated to the amount of Group

sequential chromatograpy on Hi-Trap SP ion-exchange and
Hi-Trap heparin columns. Hydrolytic activity of the eluted

been shoWn to be the most potent inducer of macrophage
65

foam cells. Kramer, R. M., et al., J Biol Chem, 1989. 264(10):

Whether Group V sPLA2 expressed by adenoviral vector

p. 5768-75. Thus, it Was of interest to determine Whether

hydrolyZes LDL Was investigated. COS-7 cells Were treated

Group V sPLA2-modi?ed LDL particles that are susceptible

US 7,521,198 B1
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to spontaneous aggregation promote foam cell formation in

lmmunocytochemical LocaliZation of Group V sPLA2 in

vitro. Peritoneal macrophages from C57BL/ 6 mice Were

Human and Mouse Atherosclerotic Lesions

As described above, several reports have identi?ed sPLA2

incubated With non-modi?ed (mock) LDL, aggregated LDL
produced by vortexing, or Group V sPLAZ-modi?ed LDL
(~30% hydrolyzed) for 48 hours. Cells Were stained With Oil

in human atherosclerotic lesions. HoWever, there are incon
sistencies in the data as to Whether sPLA2 is associated With

Red 0 and analyZed by light microscopy at 40x magni?cation.
FIG. 9. This analysis shoWed that Group V sPLAZ-modi?ed
LDL promotes macrophage foam cell formation, providing

macrophages or smooth muscle cells (SMC) in lesions. This
may be attributed to the cross-reactivity of various antibodies
With Group 11A and Group V sPLAZs. Here We used a mono

clonal antibody shoWn to be highly speci?c for human Group
V sPLA2 (Cayman Chemicals, Ann Arbor Mich.) to immun
ostain human atherosclerotic lesions. This antibody, Which
does not cross-react With Group 11A sPLA2 displayed strong

compelling evidence that this enZyme plays an important role
in the initiation and/ or progression of atherosclerosis.

Modi?cation of LDL by Group V sPLA2 promotes lipid

uptake by peritoneal macrophage cells. Mouse peritoneal

immunoreactivity (red staining) in lesional macrophages

macrophage cells Were plated (1 .8><106 cells/Well) in DMEM

(compare the staining When sections Were immunostained
With anti-CD68, a macrophage-speci?c antigen; FIG. 2A, but
not in SMC. A neWly developed rabbit anti-mouse polyclonal
antibody Was also generated by art knoWn methods and used

complete media on glass cover slips in a 6 Well dish. Non
adherent cells Were removed by Washing With serum free
DMEM after 4 hours at 370 C., and adherent cells Were
stimulated With 1 mM MCSF for 16 hours. Cells Were then

treated With 200 g/ml unmodi?ed LDL, vortexed LDL, or
Group V sPLA2 modi?ed LDL. After 48 hours at 370 C., cells
Were Washed With PBS, ?xed With 10% formalin for 10 min
utes, and Washed With 60% isopropanol. The cells Were
stained With oil Red 0 for 30 minutes and Washed again With
60% isopropanol. The cells Were then visualiZed With light
microscopy at 40x magni?cation. The results are shoWn in
FIG. 9.

to stain lesions in apoE_/_ mice. These mice are in the

C57BL/ 6 background, and therefore lack Group 11A sPLA2
20

FA-l 1.
What is claimed is:
25

patient;
(2) contacting the tissue sample With a ?rst antibody or
30

the bacterial expression plasmid pET22b (Novagen, Madi

35

With a second antibody that binds to the ?rst antibody or

antibody fragment, Wherein said second antibody has a
40

Group V antisera can be used in the same manner as anti

V sPLA2 in tissue or serum.

detectable label attached thereto.
4. The method of claim 1 Wherein the ?rst antibody or

antibody fragment is detected by contacting the sample With

cell lysates from control COS-7 cells and cells infected With
adenoviral vector expressing mouse Group V sPLA2. Anti
Group V sPLA2 antibodies to detect and/or quantitate Group

to the tissue sample.
2. The method of claim 1 Wherein the ?rst antibody or
antibody fragment has a detectable label attached thereto.
3. The method of claim 1 Wherein the ?rst antibody or

antibody fragment is detected by contacting the tissue sample

used to express full-length mouse Group V sPLA2, Which

may be puri?ed from bacterial inclusion bodies by gel ?ltra
tion (Dr. E. A. Dennis, personal communication). The immu
noreactivity of rabbit anti-mouse Group V antisera is demon
strated in FIG. 11, Which shoWs immunoblot analysis of total

antibody fragment that speci?cally binds to human
Group V sPLA2; and

(3) detecting binding of the antibody or antibody fragment

son, Wis.). The expressed protein contained a C-terminal

His'Tag, Which alloWed for one-step puri?cation by a?inity
chromatography. As shoWn in FIG. 10, use of this prokaryotic
expression system provided an e?icient method for produc
ing antigen for immuniZing rabbits. The pET system is also

1. A method of diagnosing the presence of atherosclerotic

plaques in a patient comprising:
(1) obtaining a subendothelial tissue sample from the

Development of Rabbit Anti-Mouse Group V sPLA2
To produce rabbit antisera speci?c for mouse Group V
sPLA2, sequences encoding residues 9-1 13 Were inserted into

due to a frame-shift mutation in exon 3. As shoWn in FIG. 2B,

immunostaining With anti-mouse Group V sPLA2 co-local
iZed With the macrophage-speci?c monoclonal antibody,

45

a chemical entity that binds to the ?rst antibody or antibody
fragment, Wherein the chemical entity has a detectable label
attached thereto.

